Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with uncontrolled or resistant hypertension, according to the results of a phase 3 trial announced today.